These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9468240)

  • 21. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S
    Am J Gastroenterol; 1996 Apr; 91(4):743-7. PubMed ID: 8677941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Large dose natural interferon alpha therapy for patients with chronic hepatitis C.
    Ohmiya M; Hayashi J; Furusyo N; Ueno K; Kishihara Y; Nabeshima S; Kashiwagi S
    Fukuoka Igaku Zasshi; 1997 Dec; 88(12):380-8. PubMed ID: 9465478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.
    Fried MW; Shiffman M; Sterling RK; Weinstein J; Crippin J; Garcia G; Wright TL; Conjeevaram H; Reddy KR; Peter J; Cotsonis GA; Nolte FS
    Am J Gastroenterol; 2000 Nov; 95(11):3225-9. PubMed ID: 11095346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The changes in quantitative HCV RNA titers during interferon alpha 2B therapy in patients with chronic hepatitis C infection.
    Tong MJ; Blatt LM; Conrad A; Hur Y; Russell J; El-Farra NS; Co RL
    Am J Gastroenterol; 1998 Apr; 93(4):601-5. PubMed ID: 9576455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon and steroid treatment in patients with chronic hepatitis C and antinuclear or anti-liver-kidney microsomal antibodies.
    Provenzano G; Almasio P; Fabiano C; Magrin S; Pinzello G; Vaccaro A; Craxì A
    Ital J Gastroenterol; 1996 Sep; 28(7):377-80. PubMed ID: 8937938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
    Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group.
    Shiratori Y; Moriyama M; Imazeki F; Ohkubo H; Tanaka N; Arakawa Y; Yoshida H; Yokosuka O; Shibuya A; Matsuzaki K; Hashimoto E; Hayashi N; Hirata K; Ohashi Y; Omata M
    Liver; 2000 Jul; 20(4):271-80. PubMed ID: 10959805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C.
    Diago M; Suárez D; García-Villarreal L; Castro A; Domínguez A; Pardo M; del Olmo JA; Pérez-Hernández F; Aguilar J; Quiroga JA; Carreño V
    J Med Virol; 2001 Aug; 64(4):460-5. PubMed ID: 11468730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha.
    Malaguarnera M; Di Fazio I; Restuccia S; Pistone G; Restuccia N; Trovato BA
    Ann Med; 1998 Apr; 30(2):213-7. PubMed ID: 9667801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit.
    Hadziyannis AS; Papaioannou C; Spanou F; Manesis EK; Hadziyannis SJ
    Aliment Pharmacol Ther; 2001 Apr; 15(4):551-7. PubMed ID: 11284785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C.
    Garson JA; Uhnoo I; Whitby K; Braconier JH; Deaville R; Duberg A; Wallmark E; Wiström J; Goldin RD; Spacey B
    J Viral Hepat; 1997 Sep; 4(5):325-31. PubMed ID: 9310931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type C liver cirrhosis: comparative study between increase in individual IFN dose and prolonging of treatment period, using a multicenter randomized controlled trial.
    Shinzawa H; Yoshida Y; Masamune O; Toyota T; Takahashi T; Kasukawa R; Sudo T; Ishikawa K; Komatsu M; Ishii M; Takagi T; Hisamichi S; Sato S; Ichida H
    Dig Dis Sci; 2000 Mar; 45(3):575-80. PubMed ID: 10749335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-induced anosmia in a patient with chronic hepatitis C.
    Maruyama S; Hirayama C; Kadowaki Y; Sagayama A; Omura H; Nakamoto M
    Am J Gastroenterol; 1998 Jan; 93(1):122-3. PubMed ID: 9448193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained viral response is rarely achieved in patients with high viral load of HCV RNA by excessive interferon therapy.
    Shiratori Y; Kato N; Yoshida H; Nakata R; Ihori M; Imazeki F; Yokosuka O; Kawase T; Katamoto T; Unuma T; Nakamura A; Ikegami F; Hirota K; Omata M
    Dig Dis Sci; 2000 Mar; 45(3):565-74. PubMed ID: 10749334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon alpha-2b in the treatment of chronic hepatitis C: early experience.
    Ching NP; Lumeng J; Pang R; Pang G; Or FW; Ching NW; Ching C
    Hawaii Med J; 1998 Dec; 57(12):735-9. PubMed ID: 9893388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic hepatitis C: treatment comparison between 3 and 5 million units of interferon alpha-2b.
    Castro F; Torres EA; Oharriz J; González-Keelan C; Pérez C; Rubio C
    P R Health Sci J; 1998 Sep; 17(3):221-5. PubMed ID: 9883467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.
    Shiratori Y; Nakata R; Shimizu N; Katada H; Hisamitsu S; Yasuda E; Matsumura M; Narita T; Kawada K; Omata M;
    Dig Dis Sci; 2000 Dec; 45(12):2414-21. PubMed ID: 11258568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study.
    Izumi N; Kumada H; Hashimoto N; Harada H; Imawari M; Zeniya M; Toda G
    Dig Dis Sci; 2001 Mar; 46(3):516-23. PubMed ID: 11318525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.